<DOC>
	<DOCNO>NCT00433225</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ketorolac 0.4 % quality vision macula thicken patient undergo cataract surgery use ReStor® multifocal IOL .</brief_summary>
	<brief_title>Efficacy Topical Ketorolac Versus Placebo Improving Visual Outcomes Following Multifocal IOL Implantation</brief_title>
	<detailed_description />
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Gatifloxacin</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Males female &gt; 50 year old Scheduled undergo bilateral phacoemulsification implantation multifocal IOL . Likely complete study visit able provide inform consent Visual potential 20/25 good · Prior use topical ketorolac Known contraindication study medication ingredient Active ocular disease uncontrolled systemic disease Active ocular allergy</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
</DOC>